PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.68
−1.05%Margins
Gross margin
80.7%
EBITDA margin
-7.2%
EBIT margin
-9.3%
Net margin
-30.2%
FCF margin
-7.5%
23.9%
Return on equity
-24.1%
Return on assets
14.2%
Return on invested capital
0.82x
Asset turnover
-$20.7M
Cash from operations
$2.27
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026